Self-reported Gastrointestinal Side Effects of Antifibrotic Drugs in Dutch Idiopathic Pulmonary Fibrosis Patients

Overview

Journal Lung

Specialty Pulmonary Medicine

Date 2019 Aug 24

PMID 31440832

Citations 18

Authors

V L J Proesmans

M Drent

M D P Elfferich

P A H M Wijnen

N T Jessurun

A Bast

Affiliations

Soon will be listed here.

Abstract

Purpose: Idiopathic pulmonary fibrosis (IPF) is an inexorably progressive disease, which has a great impact on patients' lives. Pirfenidone and nintedanib are approved and recommended antifibrotic drugs for patients with IPF. The aim of this study was to evaluate self-reported gastrointestinal side effects of antifibrotic drugs in 176 Dutch IPF patients.

Methods: A cross-sectional web-based anonymous survey about complaints and side effects was conducted among IPF patients in the Netherlands. Logistic regression was used to quantify whether pirfenidone and nintedanib caused complaints of nausea, vomiting, diarrhoea, appetite loss, weight loss or loss of taste or smell perception.

Results: The questionnaire was completed by 176 IPF patients, 71 of whom used pirfenidone and 85 nintedanib, while 20 patients did not use any antifibrotic drugs. Nintedanib users reported complaints of diarrhoea, vomiting, weight loss and loss of appetite (p < 0.01). Nausea was a significant adverse reaction (p < 0.05). Pirfenidone caused increased appetite loss (p < 0.01) and the risk of weight loss (p < 0.05). The increase in loss of appetite and weight loss did not differ significantly between the two drugs.

Conclusion: The current study showed that nintedanib causes a significant increase in diarrhoea, vomiting, weight loss and loss of appetite, while pirfenidone led to loss of appetite. Our results suggest new avenues regarding dietary recommendations for IPF patients.

Citing Articles

Patient-Centric Approach for the Treatment of Rheumatoid Arthritis-Associated Interstitial Lung Disease in Older People.

Mueller K, Saavedra A, OKeeffe L, Sparks J Drugs Aging. 2025; 42(2):81-94.

PMID: 39800810 DOI: 10.1007/s40266-024-01175-0.

Stage-Dependent Fibrotic Gene Profiling of WISP1-Mediated Fibrogenesis in Human Fibroblasts.

Singh K, Witek M, Brahmbhatt J, McEntire J, Thirunavukkarasu K, Oladipupo S Cells. 2024; 13(23).

PMID: 39682753 PMC: 11640464. DOI: 10.3390/cells13232005.

Timing impact on the initiation of pirfenidone therapy on idiopathic pulmonary fibrosis disease progression.

Mohamed B, Abdelrahim M World J Clin Cases. 2024; 12(32):6538-6542.

PMID: 39554893 PMC: 11438636. DOI: 10.12998/wjcc.v12.i32.6538.

YAP/TAZ Signaling in the Pathobiology of Pulmonary Fibrosis.

Papavassiliou K, Sofianidi A, Spiliopoulos F, Gogou V, Gargalionis A, Papavassiliou A Cells. 2024; 13(18.

PMID: 39329703 PMC: 11430237. DOI: 10.3390/cells13181519.

Research priorities for progressive pulmonary fibrosis in the UK.

Fabbri L, Russell A, Chaudhuri N, Adams W, Cowan K, Conway J BMJ Open Respir Res. 2024; 11(1).

PMID: 39231598 PMC: 11428979. DOI: 10.1136/bmjresp-2024-002368.

References

Corte T, Bonella F, Crestani B, Demedts M, Richeldi L, Coeck C . Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis. Respir Res. 2015; 16:116. PMC: 4581488. DOI: 10.1186/s12931-015-0276-5. View

Valeyre D, Albera C, Bradford W, Costabel U, King Jr T, Leff J . Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis. Respirology. 2014; 19(5):740-7. PMC: 4230393. DOI: 10.1111/resp.12297. View

Verhagen J . A role for lung retention in the sense of retronasal smell. Chemosens Percept. 2015; 8(2):78-84. PMC: 4635677. DOI: 10.1007/s12078-015-9181-z. View

Yount S, Beaumont J, Chen S, Kaiser K, Wortman K, Van Brunt D . Health-Related Quality of Life in Patients with Idiopathic Pulmonary Fibrosis. Lung. 2016; 194(2):227-34. DOI: 10.1007/s00408-016-9850-y. View

Bennett D, Refini R, Valentini M, Fui A, Fossi A, Pieroni M . Pirfenidone Therapy for Familial Pulmonary Fibrosis: A Real-Life Study. Lung. 2019; 197(2):147-153. DOI: 10.1007/s00408-019-00203-w. View

King Jr T, Bradford W, Castro-Bernardini S, Fagan E, Glaspole I, Glassberg M . A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014; 370(22):2083-92. DOI: 10.1056/NEJMoa1402582. View

Crestani B, Huggins J, Kaye M, Costabel U, Glaspole I, Ogura T . Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON. Lancet Respir Med. 2018; 7(1):60-68. DOI: 10.1016/S2213-2600(18)30339-4. View

Russell A, Ripamonti E, Vancheri C . Qualitative European survey of patients with idiopathic pulmonary fibrosis: patients' perspectives of the disease and treatment. BMC Pulm Med. 2016; 16:10. PMC: 4712607. DOI: 10.1186/s12890-016-0171-y. View

Williams L, Cohen M . Altered taste thresholds in lung cancer. Am J Clin Nutr. 1978; 31(1):122-5. DOI: 10.1093/ajcn/31.1.122. View

10.

Hughes G, Toellner H, Morris H, Leonard C, Chaudhuri N . Real World Experiences: Pirfenidone and Nintedanib are Effective and Well Tolerated Treatments for Idiopathic Pulmonary Fibrosis. J Clin Med. 2016; 5(9). PMC: 5039481. DOI: 10.3390/jcm5090078. View

11.

Ikeda H, Itasaka M, Takahashi K, Komatani A . Prolonged lung retention of 123I-IMP in pulmonary fibrosis. Ann Nucl Med. 1992; 6(3):147-51. DOI: 10.1007/BF03178306. View

12.

Wijsenbeek M, Grutters J, Wuyts W . Early Experience of Pirfenidone in Daily Clinical Practice in Belgium and The Netherlands: a Retrospective Cohort Analysis. Adv Ther. 2015; 32(7):691-704. PMC: 4522034. DOI: 10.1007/s12325-015-0225-1. View

13.

Duck A, Spencer L, Bailey S, Leonard C, Ormes J, Caress A . Perceptions, experiences and needs of patients with idiopathic pulmonary fibrosis. J Adv Nurs. 2014; 71(5):1055-65. PMC: 4674980. DOI: 10.1111/jan.12587. View

14.

Ito K, Kohzuki M, Takahashi T, Ebihara S . Improvement in taste sensitivity following pulmonary rehabilitation in patients with chronic obstructive pulmonary disease. J Rehabil Med. 2014; 46(9):932-6. DOI: 10.2340/16501977-1861. View

15.

Shaw J, Marshall T, Morris H, Hayton C, Chaudhuri N . Idiopathic pulmonary fibrosis: a holistic approach to disease management in the antifibrotic age. J Thorac Dis. 2017; 9(11):4700-4707. PMC: 5721024. DOI: 10.21037/jtd.2017.10.111. View

16.

Ogura T, Azuma A, Inoue Y, Taniguchi H, Chida K, Bando M . All-case post-marketing surveillance of 1371 patients treated with pirfenidone for idiopathic pulmonary fibrosis. Respir Investig. 2015; 53(5):232-41. DOI: 10.1016/j.resinv.2015.06.001. View

17.

Rubino C, Bhavnani S, Ambrose P, Forrest A, Loutit J . Effect of food and antacids on the pharmacokinetics of pirfenidone in older healthy adults. Pulm Pharmacol Ther. 2009; 22(4):279-85. DOI: 10.1016/j.pupt.2009.03.003. View

18.

Wardwell L, Chapman-Novakofski K, Brewer M . Effects of age, gender and chronic obstructive pulmonary disease on taste acuity. Int J Food Sci Nutr. 2009; 60 Suppl 6:84-97. DOI: 10.1080/09637480802710224. View

19.

Noble P, Albera C, Bradford W, Costabel U, Glassberg M, Kardatzke D . Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011; 377(9779):1760-9. DOI: 10.1016/S0140-6736(11)60405-4. View

20.

Raghu G, Collard H, Egan J, Martinez F, Behr J, Brown K . An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011; 183(6):788-824. PMC: 5450933. DOI: 10.1164/rccm.2009-040GL. View